Fred joined Venrock in 2006 and has been focused on the medical device and drug development sectors, with a special interest in Latin America. At Venrock, Fred has led multiple investments in med tech and biotech, and served on the Board of Directors of Receptos (NASDAQ: RCPT) and as an observer in a number of other portfolio companies including Zeltiq (NASDAQ:ZLTQ) and PowerVision. Fred is also founder and CEO of ADVANCE Medical, a Venrock portfolio company that is focused on the commercialization of medical technology in Brazil and other countries in Latin America. The company has raised over US$25 million since inception and has acquired a long-standing Brazilian distribution company.
Earlier in his career, Fred was director of business development and head of investor relations for CuraGen Corporation (NASDAQ: CRGN), an oncology-focused drug development company (acquired by NASDAQ: CLDX). In this role, he was responsible for strategic planning, the in-licensing of a clinical stage oncology product, securing sell-side analyst coverage and helping raise over $100 million. Prior to CuraGen, he worked at Boston Consulting Group where he advised biotechnology and pharmaceutical companies on a number of strategic initiatives.
Fred received his B.S. in Biology from Duke University, M.D. from Yale University School of Medicine and M.B.A. from the Harvard Business School. He was born and raised in Brazil but has lived in the US for over 20 years.